Sonnet Biotherapeutics

Yahoo Finance • 5 days ago

Heights Capital Walks From Archer Aviation: What It Means for Investors

Key Points Sold 2,312,285 shares of Archer Aviation, a net change of approximately $25.09 million Post-trade stake: zero shares, valued at $0 The Archer Aviation position previously accounted for about 6.2% of the fund’s AUM as of the pri... Full story

Yahoo Finance • 5 days ago

Heights Capital Just Ditched Its $12.5 Million AMSC Stake. Here’s What That Might Mean.

Key Points Exited 340,102 shares in American Superconductor, reducing position value by $12.48 million Post-trade stake is zero shares, or $0 value The position was previously 3.3% of the fund's AUM as of the prior quarter These 10 stocks... Full story

Yahoo Finance • last month

Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma

HOUSTON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) is collaborating with Spanios on a non-clinical study using New Alternate Methodologies (NAM)-based patient-derived tumoroid (PDT) platforms t... Full story

Yahoo Finance • 2 months ago

Sonnet to Present at the MedInvest Biotech & Pharma Conference

PRINCETON, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME)... Full story

Yahoo Finance • 3 months ago

Sonnet Releases Virtual Investor "What This Means" Segment

- Dr. Richard Kenney, Chief Medical Officer of Sonnet, discusses the recently announced expansion of its clinical study of patients with platinum-resistant ovarian cancer (PROC) (SB221) - Watch the "What This Means" video here PRINCETON,... Full story

Yahoo Finance • 4 months ago

This Cancer Biotech Company Is Making a Big Bet on the HYPE Crypto. Should You Buy Its Stock Here?

Michael Saylor-led MicroStrategy (MSTR) [https://www.barchart.com/quotes/MSTR] started it in 2020. Now, from Tesla (TSLA) [https://www.barchart.com/quotes/TSLA] to Block (XYZ) [https://www.barchart.com/quotes/XYZ] to even the federal gover... Full story

Yahoo Finance • 4 months ago

Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

Sonnet's lead product, SON-1010 (IL12-FHAB), is being evaluated in combination with atezolizumab (Tecentriq®) in patients with advanced platinum-resistant ovarian cancer (PROC) (SB221) Topline safety, cytokine, and efficacy data suggest a... Full story

Yahoo Finance • 4 months ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SONN, FCCO, MGRM on Behalf of Shareholders

NEW YORK, July 19, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story

Yahoo Finance • 4 months ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VRNA, KLG, MRGM, SONN on Behalf of Shareholders

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story

Yahoo Finance • 4 months ago

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Sonnet BioTherapeutics, Inc. (NASDAQ: SONN)

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in th... Full story

Yahoo Finance • 4 months ago

Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy

PRINCETON, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics, Inc., (NASDAQ: SONN) (“Sonnet” or the “Company”) today announced that it has entered into a definitive agreement (the “Business Combination Agreement”, or the “BC... Full story

Yahoo Finance • 5 months ago

Sonnet BioTherapeutics completes $2 million convertible note and warrant sale

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a biotech company with a market capitalization of $3.83 million and maintaining more cash than debt on its balance sheet according to InvestingPro data, announced the completion of a pri... Full story

Yahoo Finance • 8 months ago

Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

Topline safety data in SB221 study suggest clinical benefit of SON-1010 in combination with atezolizumab (Tecentriq®) The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg in combination with atezolizumab in patients with pla... Full story

Yahoo Finance • 8 months ago

Sonnet Announces Release of Corporate Update Video

PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME)... Full story

Yahoo Finance • 8 months ago

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME)... Full story

Yahoo Finance • 8 months ago

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

SON-1010 is being studied as a combination therapy with trabectedin (Yondelis®), the first FDA-approved treatment for two types of advanced soft tissue sarcoma after failure of standard chemotherapy, due to the potential for immune mechani... Full story

Yahoo Finance • 8 months ago

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein

Company advancing development of its modified version of Interleukin-18 (IL-18Binding Protein Resistant or IL-18BPR) that exhibits wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18... Full story

Yahoo Finance • 8 months ago

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

On-demand video webcast now available here PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeu... Full story

Yahoo Finance • 9 months ago

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

Poster presented at the 2025 AACR:IO Conference Company’s novel platform that delivers either mono- or bifunctional immunomodulators linked to a Fully-Human, Albumin Binding scFv domain (FHAB®) provides enhanced targeting to the tumor mic... Full story

Yahoo Finance • 9 months ago

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

Building on proven targeting of the FHAB domain, Sonnet’s ADC platform offers flexible payload capacity and controllable drug-antibody ratios (DAR) An epidermal growth factor receptor 2 (HER2) ADC construct designated – SON-5010 showed si... Full story